IP Verse

Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists

PatentPatent Analysis

EP3283882

MERCK SHARP & DOHME
Application Number
EP16780526A
Filing Date
Apr 12, 2016
Status
Patent Maintained As Amended
Sep 13, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3165220B2
EP3678654B1
EP1841493B2

Biblio Summary

The patent EP3283882B2 was granted to Merck Sharp & Dohme on Oct 16, 2024 following the initial filing on Apr 12, 2016 under the application number EP16780526A . The current legal status of the patent is Patent Maintained As Amended.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SYMBIOSISSep 15, 2021ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents